P S Kamath

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension
    P S Kamath
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Hepatology 30:401-7. 1999
  2. pmc The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure
    Patrick S Kamath
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 13:63-6. 2009
  3. ncbi request reprint Portopulmonary hypertension and hepatopulmonary syndrome
    Patrick S Kamath
    Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Gastroenterol Hepatol 17:S253-5. 2002
  4. ncbi request reprint Esophageal variceal bleeding: primary prophylaxis
    Patrick S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 3:90-3. 2005
  5. ncbi request reprint Scoring severity of chronic liver disease
    Patrick S Kamath
    Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    J Gastroenterol Hepatol 17:S298-9. 2002
  6. ncbi request reprint Budd-Chiari syndrome: Radiologic findings
    Patrick S Kamath
    Division of GI and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:S21-2. 2006
  7. ncbi request reprint The model for end-stage liver disease (MELD)
    Patrick S Kamath
    Advanced Liver Disease Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:797-805. 2007
  8. ncbi request reprint Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver
    P S Kamath
    Departments of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 6:596-602. 2000
  9. ncbi request reprint Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis
    P S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 118:905-11. 2000
  10. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004

Detail Information

Publications65

  1. ncbi request reprint Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension
    P S Kamath
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Hepatology 30:401-7. 1999
    ..We conclude that in a BDL model of portal hypertension where distortion of hepatic architecture by fibrosis is minimal, increased resistance to portal blood flow may be mediated by ET-1...
  2. pmc The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure
    Patrick S Kamath
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 13:63-6. 2009
    ..8, indicating excellent discrimination...
  3. ncbi request reprint Portopulmonary hypertension and hepatopulmonary syndrome
    Patrick S Kamath
    Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Gastroenterol Hepatol 17:S253-5. 2002
  4. ncbi request reprint Esophageal variceal bleeding: primary prophylaxis
    Patrick S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 3:90-3. 2005
  5. ncbi request reprint Scoring severity of chronic liver disease
    Patrick S Kamath
    Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    J Gastroenterol Hepatol 17:S298-9. 2002
  6. ncbi request reprint Budd-Chiari syndrome: Radiologic findings
    Patrick S Kamath
    Division of GI and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:S21-2. 2006
    ..6. Transjugular intrahepatic portosystemic shunt provides definitive treatment in many patients; this is not discussed...
  7. ncbi request reprint The model for end-stage liver disease (MELD)
    Patrick S Kamath
    Advanced Liver Disease Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:797-805. 2007
    ..It is possible that the addition of variables that are better determinants of liver and renal function may improve the predictive accuracy of the model. Efforts at further refinement and validation of the MELD score will continue...
  8. ncbi request reprint Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver
    P S Kamath
    Departments of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 6:596-602. 2000
    ..In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture...
  9. ncbi request reprint Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis
    P S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 118:905-11. 2000
    ..The response of gastric mucosal lesions in cirrhotic patients with portal hypertension, namely, portal hypertensive gastropathy (PHG) and gastric vascular ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known...
  10. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004
    ..Delta MELD is predictive of death only within 4 d of the event; however, part of this correlates with the dying process itself, thus limiting Delta MELD's utility in survival prediction models...
  11. doi request reprint Serum sodium, renal function, and survival of patients with end-stage liver disease
    Young Suk Lim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Hepatol 52:523-8. 2010
    ..We investigate the role of serum creatinine and sodium, and glomerular filtration rate (GFR) as determinants of survival in patients with ESLD...
  12. ncbi request reprint Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia
    D K Tack
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:895-7. 2001
    ..The possible association between Mylotarg infusion and HVOD is discussed...
  13. doi request reprint Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis
    K Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Gut 57:814-20. 2008
    ..The aim of this study was to determine risk factors for 6-week mortality, and re-bleeding within 5 days in patients with cirrhosis and AVH...
  14. ncbi request reprint Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease
    Charmaine A Stewart
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 13:1366-71. 2007
    ..HE may provide additional prognostic information independent of MELD, which warrants prospective validation...
  15. doi request reprint Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis
    Mark Topazian
    Miles and Shirley Fiterman Center for Digestive Diseases, Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55906, USA
    Clin Gastroenterol Hepatol 6:364-6. 2008
    ..Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy...
  16. ncbi request reprint Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 47:332-42. 2008
    ..hepatology 2007.)...
  17. doi request reprint Hyponatremia and mortality among patients on the liver-transplant waiting list
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 359:1018-26. 2008
    ..Under the current liver-transplantation policy, donor organs are offered to patients with the highest risk of death...
  18. ncbi request reprint Medical and ethical aspects of long-term enteral tube feeding
    M Molly McMahon
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1461-76. 2005
    ..We present our multidisciplinary approach that combines medical, nutritional, and ethical principles for the care of these patients...
  19. doi request reprint A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices
    Roman E Perri
    Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 47:1587-94. 2008
    ..CONCLUSION: Abdominal CT as the initial screening test for varices could be cost-effective. CT also permits evaluation of extra-luminal pathology that impacts management...
  20. ncbi request reprint An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 116:759-66. 2004
    ..In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues...
  21. ncbi request reprint Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation
    Joseph J Ocel
    Mayo Medical School, Division of Anatomic Pathology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:492-501. 2004
    ..To determine underlying conditions in patients undergoing both heart and liver biopsies...
  22. ncbi request reprint Influence of recent advances in medical management on clinical outcomes of cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1501-8. 2005
    ....
  23. ncbi request reprint MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients
    Walter K Kremers
    The William J von Liebig Transplant Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:764-9. 2004
    ..68). In conclusion, liver allocation within the Status 1 designation may need to be further stratified by diagnosis, and MELD score may be useful for prioritizing FHF-NA candidates...
  24. ncbi request reprint Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis
    Jayant A Talwalkar
    Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:431-5. 2003
    ..To determine the level of association between minimal listing criteria (MLC) recognition and outcomes associated with waiting list registration for liver transplantation (LT)...
  25. ncbi request reprint Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy
    Susan C Abraham
    Department of Pathology and Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 30:1454-61. 2006
    ..The occurrence of NRH in some patients transplanted for other indications suggests it is a histologic pattern that can precede the development of clinically significant portal hypertension...
  26. ncbi request reprint Nitric oxide in liver transplantation: pathobiology and clinical implications
    Vijay Shah
    GI Research Unit and Advanced Liver Disease Study Group, Department of Medicine, Alfred 2 435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 9:1-11. 2003
    ..This review article focuses on new advances relating to the role of nitric oxide in these syndromes with an emphasis on pathobiology and potential clinical implications...
  27. ncbi request reprint Ectopic varices in the gastrointestinal tract: short- and long-term outcomes of percutaneous therapy
    Thanila A Macedo
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Intervent Radiol 28:178-84. 2005
    ..TIPS can offer good control of bleeding at the expense of a more complex procedure and associated risk of encephalopathy...
  28. pmc Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis
    Brianna E Vaa
    Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:37-42. 2011
    ....
  29. doi request reprint Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension
    N Chandok
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 35:904-12. 2012
    ..It remains unclear whether a long-acting preparation of octreotide (Sandostatin LAR) can be safely used for portal hypertension in patients with compensated cirrhosis...
  30. doi request reprint Hypermanganesemia, hereditary hemorrhagic telangiectasia, brain abscess: the hepatic connection
    N Kumar
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 71:1118-9. 2008
  31. ncbi request reprint Risk factors for mortality after surgery in patients with cirrhosis
    Swee H Teh
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 132:1261-9. 2007
    ..The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis...
  32. ncbi request reprint MELD accurately predicts mortality in patients with alcoholic hepatitis
    Winston Dunn
    Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 41:353-8. 2005
    ..MELD is a useful clinical tool for gauging mortality and guiding treatment decisions in patients with AH, particularly those complicated by ascites and/or encephalopathy...
  33. doi request reprint Current staging and diagnosis of gastroesophageal varices
    Nayantara Coelho-Prabhu
    Mayo Clinic Rochester, MN 55905, USA
    Clin Liver Dis 14:195-208. 2010
    ..Cirrhosis is the most common cause of portal hypertension in the western world and results from increased resistance to blood flow at the hepatic sinusoidal level...
  34. ncbi request reprint Performance standards for therapeutic abdominal paracentesis
    Catherine M Grabau
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 40:484-8. 2004
    ....
  35. ncbi request reprint Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation
    Harshad Devarbhavi
    Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Liver Transpl 13:1552-6. 2007
    ..Intervention aimed at correcting the vascular abnormalities in these patients may result in clinical as well as hepatic histological improvement...
  36. ncbi request reprint Cancer antigen 125 in patients with chronic liver disease
    Harshad Devarbhavi
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:538-41. 2002
    ....
  37. ncbi request reprint Regional and systemic hemodynamic disturbances in cirrhosis
    K V Menon
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Clin Liver Dis 5:617-27, viii. 2001
    ..These imbalances result in portal hypertension, hepatorenal syndrome, portopulmonary hypertension, hepatopulmonary syndrome, as well as alterations in cerebral blood flow...
  38. ncbi request reprint A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis
    K V Narayanan Menon
    Advanced Liver Disease Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:255-60. 2004
    ....
  39. pmc A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis
    Nicholas C Boetticher
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1953-60. 2008
    ..A pilot study demonstrated that the TNF-alpha-neutralizing molecule etanercept could be an effective treatment for patients with alcoholic hepatitis...
  40. ncbi request reprint Cardiac surgery in kidney and liver transplant recipients
    Subrato J Deb
    Division of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:917-22. 2006
    ..To evaluate operative management, outcome, and long-term survival in patients with functioning renal and hepatic allografts who underwent cardiac surgery...
  41. ncbi request reprint Transjugular intrahepatic portosystemic shunts: an update
    Barbara Rosado
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 9:207-17. 2003
    ..The MELD score may be useful in predicting post-TIPS survival, and also in counseling patients and their families...
  42. ncbi request reprint The Budd-Chiari syndrome
    K V Narayanan Menon
    Advanced Liver Disease Study Group, Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 350:578-85. 2004
  43. ncbi request reprint Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:997-9. 2001
    ..Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action...
  44. pmc Utility of a new model to diagnose an alcohol basis for steatohepatitis
    Winston Dunn
    Advanced Liver Disease Study Group and Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 131:1057-63. 2006
    ..Thus, the aim of our study was to create and validate a model to diagnose ALD in patients with steatohepatitis...
  45. ncbi request reprint Cardiomyopathy associated with celiac disease
    Nisheeth K Goel
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:674-6. 2005
    ..However, with early diagnosis and treatment with a gluten-free diet, cardiomyopathy in patients with celiac disease may be completely reversible...
  46. ncbi request reprint Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites
    Luke T Evans
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 37:897-901. 2003
    ..In addition, the organisms cultured from ascitic fluid in outpatients are predominantly gram positive. A reassessment of diagnostic criteria for spontaneous bacterial peritonitis in outpatients may be required...
  47. ncbi request reprint Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD)
    Magdalena Adeva
    Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Medicine (Baltimore) 85:1-21. 2006
    ..The current study indicates a broadened spectrum for the ARPKD phenotype and that later presenting cases with predominant liver disease should be considered part of ARPKD...
  48. ncbi request reprint Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:589-98. 2003
    ..In this review, we provide a comprehensive account of the pathophysiology of this disease as we understand it today, risk factors for its development, and the current state of knowledge regarding preventive and therapeutic options...
  49. ncbi request reprint Acute superior mesenteric venous thrombosis: one disease or two?
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Gastroenterol 98:1299-304. 2003
    ..The aim of this study was to determine the etiology and natural history of acute superior mesenteric venous thrombosis (MVT) with and without splenic or portal vein involvement...
  50. ncbi request reprint Clinical profile of autosomal dominant polycystic liver disease
    Qi Qian
    Division of Nephrology, Mayo Clinic, Rochester, MN, USA
    Hepatology 37:164-71. 2003
    ..In conclusion, isolated ADPLD is underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with similar pathogenesis, manifestations, and management...
  51. ncbi request reprint Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid
    William Sanchez
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:541-4. 2006
    ..Usnic acid hepatotoxicity should be considered as a possible etiologic factor in patients presenting with fulminant hepatic failure, especially if they have been taking dietary supplements for weight reduction...
  52. pmc Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Department of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
    AJR Am J Roentgenol 193:122-7. 2009
    ..The purposes of this study were to determine the feasibility of measuring spleen stiffness with MR elastography and to prospectively test the technique in healthy volunteers and in patients with compensated liver disease...
  53. ncbi request reprint Hematological malignancy manifesting as ascites
    Konstantinos N Lazaridis
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 2:112-6; quiz 117. 2005
    ..Splenectomy was recommended but the patient declined. She was lost to follow-up twice but returned with tense ascites about 2 years after the initial presentation. Despite aggressive medical management, the ascites did not improve...
  54. ncbi request reprint Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis
    Pere Gines
    Liver Unit, Hospital Clinic, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, University of Barcelona, Instituto Reina Sofia de Investigacion Nefrologica, Barcelona, Catalunya, Spain
    Gastroenterology 123:1839-47. 2002
    ..However, its effect on survival and healthcare costs is still uncertain...
  55. ncbi request reprint Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Liver Transpl 13:867-74. 2007
    ..65-0.85). In conclusion, MELD showed a suboptimal discriminative ability to predict survival in BCS. This was explained by the highly variable degree of liver dysfunction and hence clinical outcome in BCS in contrast to ESLD...
  56. ncbi request reprint Liver transplantation for severe intrahepatic noncirrhotic portal hypertension
    Alyssa M Krasinskas
    Departments of Pathology, University of Pittsburgh, PA, USA
    Liver Transpl 11:627-34; discussion 610-1. 2005
    ..Importantly, however, a diagnosis of cirrhosis is not required in this group of patients to qualify them for OLT, and these patients have good long-term graft function after OLT...
  57. doi request reprint The need for better clinical trials
    Patrick S Kamath
    Hepatology 48:1-3. 2008
  58. ncbi request reprint Is the change in MELD score a better indicator of mortality than baseline MELD score?
    Patrick S Kamath
    Liver Transpl 9:19-21. 2003
  59. doi request reprint Liver transplantation for Budd-Chiari syndrome: when is it really necessary?
    Sarwa Darwish Murad
    Liver Transpl 14:133-5. 2008
  60. ncbi request reprint Hepatic vein pressure gradient >10 mm Hg: prognostic or reflective?
    W Ray Kim
    Gastroenterology 134:641; author reply 641-2. 2008
  61. pmc Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
    Airong Li
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06519, USA
    Am J Hum Genet 72:691-703. 2003
    ..In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function mutations in PRKCSH, and the two-hit mechanism operational in dominant polycystic kidney disease, ADPLD may also occur by a two-hit mechanism...
  62. ncbi request reprint Sinusoidal dilatation and congestion in liver biopsy: is it always due to venous outflow impairment?
    Sanjay Kakar
    Department of Pathology, Veteran Affairs and University of California Medical Center, San Francisco, Calif, USA
    Arch Pathol Lab Med 128:901-4. 2004
    ..Objectives.-To determine the specificity of SDC in liver biopsies for venous outflow impairment and to seek an explanation for SDC in patients without clinical or radiologic features of venous outflow impairment...
  63. ncbi request reprint Wilson Disease--keeping the bar for diagnosis raised
    Roman E Perri
    Hepatology 42:974. 2005
  64. pmc Predictive indices of morbidity and mortality after liver resection
    David M Nagorney
    Ann Surg 244:635; author reply 637. 2006
  65. ncbi request reprint Is there life in MARS?
    Patrick S Kamath
    Hepatology 36:1017-9. 2002